Inventor · disambiguated record
Urs Schwitter
Also filed as: SCHWITTER URS
21 granted patents·12 pending applications·73 citations·filing 2004–2024
92Inventor score
Files withHOFFMANN LA ROCHE23BUBENDORF ANDRE5RIVER 3 RENAL CORP3IBRAHIM PRABHA N1ORYZON GENOMICS SA1
Top patents by PatentIndex Score
33 records- 0195US8865735B2Solid forms of a pharmaceutically active substanceIBRAHIM PRABHA N·Filed 2012·Granted Oct 21, 2014·56 cites·30 claims
- 0284US11814354B2Solid formsRIVER 3 RENAL CORP·Filed 2022·Granted Nov 14, 2023·1 cites·17 claims
- 0382US11230559B2Solid forms of [(1 S)-1 -[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-D]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-Yl]proptl] acetateHOFFMANN LA ROCHE·Filed 2018·Granted Jan 25, 2022·4 cites·13 claims
- 0479US9676793B2Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the sameHOFFMANN LA ROCHE·Filed 2015·Granted Jun 13, 2017·2 cites·19 claims
- 0577US11040977B2Synthesis of trans-8-chloro-5-methyl-1-[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10B-tetraaza-benzo[e]azulene and crytalline forms thereofHOFFMANN LA ROCHE·Filed 2019·Granted Jun 22, 2021·1 cites·2 claims
- 0677US10246460B2Synthesis of trans-8-chloro-5-methyl-1-[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10B-tetraaza-benzo[E]azulene and crytalline forms thereofHOFFMANN LA ROCHE·Filed 2016·Granted Apr 2, 2019·2 cites·6 claims
- 0777US10221125B2Solid formsORYZON GENOMICS SA·Filed 2016·Granted Mar 5, 2019·2 cites·34 claims
- 0872US12134599B2Solid formsRIVER 3 RENAL CORP·Filed 2023·Granted Nov 5, 2024·0 cites·20 claims
- 0972US7409041B2Methods of transmission mode X-ray diffraction analysis and apparatuses thereforHOFFMANN LA ROCHE·Filed 2006·Granted Aug 5, 2008·4 cites·50 claims
- 1070US12459947B2Synthesis of trans-8-chloro-5-methyl-1 -[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10B-tetraaza-benzo[e]azulene and crystalline forms thereofHOFFMANN LA ROCHE·Filed 2021·Granted Nov 4, 2025·0 cites·2 claims
- 1169US2025263378A1Solid formsRIVER 3 RENAL CORP·Filed 2024·Application pending·0 cites
- 1268US2025109149A1Forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of makingHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 1366US8039473B2Solid forms of [4-(3-fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanoneHOFFMANN LA ROCHE·Filed 2010·Granted Oct 18, 2011·1 cites·13 claims
- 1461US12122789B2Forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of makingHOFFMANN LA ROCHE·Filed 2021·Granted Oct 22, 2024·0 cites·31 claims
- 1559US12012420B2Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetateHOFFMANN LA ROCHE·Filed 2021·Granted Jun 18, 2024·0 cites·16 claims
- 1659US12012421B2Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetateHOFFMANN LA ROCHE·Filed 2021·Granted Jun 18, 2024·0 cites·13 claims
- 1757US2010093808A1Salt and polymorph of a dpp-iv inhibitorBUBENDORF ANDRE·Filed 2009·Application pending·0 cites
- 1855US8975397B2Solid formsHOFFMANN LA ROCHE·Filed 2014·Granted Mar 10, 2015·0 cites·8 claims
- 1955US2008214561A1Solid forms of [4-(3-fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl-[5-methanesulfonyl-2-((s)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanoneBUBENDORF ANDRE·Filed 2007·Application pending·0 cites
- 2055US2013197225A1New Solid Forms of [4-(3-Fluoro-5-Trifluoromethyl-Pyridin-2-Yl)-Piperazin-1-Yl-[5-Methanesulfonyl-2-((S)-2,2,2-Trifluoro-1-Methyl-Ethoxy)-Phenyl]MethanoneHOFFMANN LA ROCHE·Filed 2013·Application pending·0 cites
- 2151US8785435B2Solid formsHOFFMANN LA ROCHE·Filed 2012·Granted Jul 22, 2014·0 cites·8 claims
- 2250US2012309969A1Solid forms of [4-(3-fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl-[5-methanesulfonyl-2-((s)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanoneBUBENDORF ANDRE·Filed 2012·Application pending·0 cites
- 2349US2007142436A1New salt and polymorph of a DPP-IV inhibitorBUBENDORF ANDRE·Filed 2006·Application pending·0 cites
- 2448US10919041B2Preparing and analyzing solid form properties of a substanceHOFFMANN LA ROCHE·Filed 2017·Granted Feb 16, 2021·0 cites·16 claims
- 2548US2023120311A1Salts and crystalline forms of a taar1 agonistHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 2648US2011295007A1Solid forms of [4-(3-fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl-[5-methanesulfonyl-2-((s)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanoneBUBENDORF ANDRE·Filed 2011·Application pending·0 cites
- 2745US2017281602A1Solid forms of (s)-2-methoxy-3--propionic acid and of salts thereofHOFFMANN LA ROCHE·Filed 2017·Application pending·0 cites
- 2844US9562009B2Process to manufacture N-[(3S)-1-[4-[(3-fluorophenyl)methoxy]phenyl]-5-oxo-pyrrolidin-3-yl]acetamideHOFFMANN LA ROCHE·Filed 2016·Granted Feb 7, 2017·0 cites·16 claims
- 2942US7160881B2Crystalline modifications of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1 λ6-thiomorpholin-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramideHOFFMANN LA ROCHE·Filed 2004·Granted Jan 9, 2007·0 cites·6 claims
- 3040US7772264B2Salt and polymorphs of a DPPIV inhibitorHOFFMANN LA ROCHE·Filed 2006·Granted Aug 10, 2010·0 cites·5 claims
- 3139US2015182505A1Solid forms of (s)-2-methoxy-3--propionic acid and of salts thereofHOFFMANN LA ROCHE·Filed 2015·Application pending·0 cites
- 3238US2019293576A1Sample holder for analyzing solid form properties of a substanceHOFFMANN LA ROCHE·Filed 2017·Application pending·0 cites
- 3337US10227298B2Solid forms of a pharmaceutically active compoundHOFFMANN LA ROCHE·Filed 2015·Granted Mar 12, 2019·0 cites·12 claims
Join the waitlist — get patent alerts
Get an alert when Urs Schwitter files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →